Cancer Genetics (NASDAQ: CGIX) and Select Medical (NYSE:SEM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
This is a breakdown of recent ratings and price targets for Cancer Genetics and Select Medical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cancer Genetics presently has a consensus price target of $6.00, suggesting a potential upside of 200.00%. Select Medical has a consensus price target of $19.50, suggesting a potential upside of 8.33%. Given Cancer Genetics’ stronger consensus rating and higher probable upside, research analysts plainly believe Cancer Genetics is more favorable than Select Medical.
This table compares Cancer Genetics and Select Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
11.1% of Cancer Genetics shares are held by institutional investors. Comparatively, 77.9% of Select Medical shares are held by institutional investors. 21.3% of Cancer Genetics shares are held by company insiders. Comparatively, 19.9% of Select Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Cancer Genetics and Select Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cancer Genetics||$27.05 million||2.05||-$15.80 million||($0.82)||-2.44|
|Select Medical||$4.29 billion||0.56||$115.41 million||$0.72||25.00|
Select Medical has higher revenue and earnings than Cancer Genetics. Cancer Genetics is trading at a lower price-to-earnings ratio than Select Medical, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Cancer Genetics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Select Medical has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.
Select Medical beats Cancer Genetics on 10 of the 14 factors compared between the two stocks.
About Cancer Genetics
Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.
About Select Medical
Select Medical Holdings Corporation is an operator of specialty hospitals, outpatient rehabilitation clinics and occupational medicine centers in the United States. The Company’s segments include specialty hospitals, outpatient rehabilitation, Concentra and Other. The specialty hospitals segment consists of hospitals designed to serve the needs of long term acute patients and hospitals designed to serve patients that require intensive medical rehabilitation care. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. The Concentra segment consists of medical centers and contract services provided at employer worksites and Department of Veterans Affairs community-based outpatient clinics (CBOCs) that deliver occupational medicine, physical therapy, veteran’s healthcare, and consumer health services. As of December 31, 2016, the Company had operations in 46 states and the District of Columbia.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.